Table 1. Characteristics of 8 cases before surgery.

Case	Gender	Age, years	Histology	c-stagea	PD-L1 TPS	Neoadjuvant chemoimmunotherapy regimen
1	Male	63	SCC	T3N2M0, IIIb	–	Albumin-bound paclitaxel 400 g d1 + cisplatin 60 mg d1–d2 + sintilimab 200 mg d2, 2 cycles
2	Male	77	SCC	T4N2M0, IIIb	–	Albumin-bound paclitaxel 300 g d1 + carboplatin 60 mg d1 + sintilimab 200 mg d2, 2 cycles
3	Female	40	SCC	T4N3M0, IIIc	–	Albumin-bound paclitaxel 300 g d1 + cisplatin 60 mg d1, 30 mg d2–d3 + sintilimab 200 mg d3, 3 cycles
4	Male	72	SCC	T3N2M0, IIIb	–	Paclitaxel liposome 240 mg d1 + cisplatin 120 mg d1 + sintilimab 200 mg d2, 2 cycles
5	Male	70	SCC	T2bN2M0, IIIb	–	Albumin-bound paclitaxel 400 mg d1 + cisplatin 30 mg d1–d3 + sintilimab 200 mg d5, 1 cycle
6	Male	65	SCC	T3N2M0, IIIb	–	Paclitaxel liposome 210 mg d1 + cisplatin 60 mg d1–d2 + sintilimab 200 mg d2, 2 cycles
7	Male	65	AD	T4N2M0, IIIb	<1%	Pemetrexed disodium 0.8 g d1 + lobaplatin 50 mg d1 + sintilimab 200 mg d2, 2 cycles
8	Male	67	AD	T1bN2M0, IIIa	90%	Pemetrexed disodium 0.95 g d1 + cisplatin 50 mg d1–d3 + sintilimab 200 mg d2, 2 cycles

^a, c-stage, clinical stage at the time of first diagnosis, according to the 8^th edition of TNM staging system. –, not detected; AD, adenocarcinoma; PD-L1, programmed cell death ligand 1; SCC, squamous cell carcinoma; TNM, tumor node metastasis; TPS, tissue polypeptide specific antigen.